8-4-2011

Extended Interferon-Alpha Therapy Accelerates Telomere Length Loss in Human Peripheral Blood T Lymphocytes

Joel M. O’Bryan
James A. Potts
Herbert L. Bonkovsky
Anuja Mathew
Alan L. Rothman
University of Rhode Island, alan_rothman@uri.edu

Follow this and additional works at: https://digitalcommons.uri.edu/immunology_facpubs
Terms of Use
All rights reserved under copyright.

Citation/Publisher Attribution
O’Bryan, J. M., Potts, J. A., Bonkovsky, H. L., Matthew, A., Rothman, A. L., et al. (2011). Extended Interferon-Alpha Therapy Accelerates Telomere Length Loss in Human Peripheral Blood T Lymphocytes. PLoS ONE, 6(8): e20922.
Available at: http://dx.doi.org/10.1371/journal.pone.0020922

This Article is brought to you for free and open access by the Institute for Immunology and Informatics (iCubed) at DigitalCommons@URI. It has been accepted for inclusion in Institute for Immunology and Informatics Faculty Publications by an authorized administrator of DigitalCommons@URI. For more information, please contact digitalcommons-group@uri.edu.
Extended Interferon-Alpha Therapy Accelerates Telomere Length Loss in Human Peripheral Blood T Lymphocytes

Creative Commons License

This work is licensed under a Creative Commons Attribution 3.0 License.

Terms of Use
All rights reserved under copyright.

This article is available at DigitalCommons@URI: https://digitalcommons.uri.edu/immunology_facpubs/29
Extended Interferon-Alpha Therapy Accelerates Telomere Length Loss in Human Peripheral Blood T Lymphocytes

Joel M. O’Bryan¹, James A. Potts¹, Herbert L. Bonkovsky²,³, Anuja Mathew¹*, Alan L. Rothman¹, for the HALT-C Trial Group

¹ Department of Medicine, University of Massachusetts Medical School, Worcester, Massachusetts, United States of America, ² Department of Medicine, University of Connecticut Health Center, Farmington, Connecticut, United States of America, ³ Carolina Medical Center, Charlotte, North Carolina, United States of America, ⁴ Institute for Immunology and Informatics, University of Rhode Island, Providence, Rhode Island, United States of America

Abstract

Background: Type I interferons have pleiotropic effects on host cells, including inhibiting telomerase in lymphocytes and antiviral activity. We tested the hypothesis that long-term interferon treatment would result in significant reduction in average telomere length in peripheral blood T lymphocytes.

Methods/Principal Findings: Using a flow cytometry-based telomere length assay on peripheral blood mononuclear cell samples from the Hepatitis-C Antiviral Long-term Treatment against Cirrhosis (HALT-C) study, we measured T cell telomere lengths at screening and at months 21 and 45 in 29 Hepatitis-C virus infected subjects. These subjects had failed to achieve a sustained virologic response following 24 weeks of pegylated-interferon-alpha plus ribavirin treatment and were subsequently randomized to either a no additional therapy group or a maintenance dose pegylated-IFNα group for an additional 3.5 years. Significant telomere loss in naïve T cells occurred in the first 21 months in the interferon-alpha group. Telomere losses were similar in both groups during the final two years. Expansion of CD8+CD45RA-CD57⁺ memory T cells and an inverse correlation of alanine aminotransferase levels with naïve CD8⁺ T cell telomere loss were observed in the control group but not in the interferon-alpha group. Telomere length at screening inversely correlated with Hepatitis-C viral load and body mass index.

Conclusions/Significance: Sustained interferon-alpha treatment increased telomere loss in naïve T cells, and inhibited the accumulation of T cell memory expansions. The durability of this effect and consequences for immune senescence need to be defined.

Introduction

Telomeres are repetitive DNA sequences, consisting of hundreds to thousands of double-stranded repeats, found at both ends of every chromosome [1]. A normal cell’s replicative potential has been linked to a combination of its telomere length (TL) and the ability to express telomerase. Telomerase assists in TL maintenance and slows telomere erosion during activation-induced proliferation of T lymphocytes [2,3]. Type I interferons (IFN), in addition to anti-viral and anti-proliferative effects, inhibit expression and activity of telomerase [4]. IFN also commonly causes lymphopenia [5], which is a stimulus for homeostatic proliferation [6]. How these competing IFN responses combine to modulate TL in peripheral naïve and memory T cells is currently unclear.

Combination pegylated-IFNα (peg-IFNα) with ribavirin is the standard therapy for subjects with chronic hepatitis C virus (cHCV) infection. Unfortunately, therapy results in a sustained virologic response (SVR) in less than 50% of HCV subjects [7]. After decades of cHCV, many patients progress to liver cirrhosis and subsequent hepatic failure, and are at risk for developing hepatocellular carcinoma [8]. The Hepatitis C Antiviral Long-term Treatment against Cirrhosis (HALT-C) trial was a clinical trial designed to assess whether sustained peg-IFNα reduced the progression of liver disease in subjects who did not achieve SVR.
Telomere Loss following IFN Therapy

Results

FlowFISH telomere length analysis in T lymphocytes

Telomere length (TL) was measured using a modified flowFISH assay [21]. We incorporated a pre-hybridization RNase treatment into the telomere flowFISH assay to minimize probe binding to telomeric RNA [22], as well as a novel set of hybridization-compatible CD4+ and CD8+ markers. This approach combined with previously described anti-CD45RA and anti-CD57 flowFISH staining allowed for quantitative estimation of average TL and frequency in T cell subsets. Inter-assay and intra-assay variations for TL estimation were additionally assessed (see Materials and Methods).

Flow cytometry gating allowed discrimination of CD4+ and CD8+ T cell subsets and estimation of TL in each subset (Fig. 1A). Although the hybridization reduced the intensity of CD8+ staining (Figure 1A, far right panel), these two primary T cell subsets (CD4+CD8− versus CD4+CD8+) could be discriminated. Within each subset, CD45RA discriminated memory (CD45RA−) T cells from the mostly naive (CD45RA+) T cell subset and CD57 further enhances discrimination of naive (CD45RA−CD57+) T cells from CD57− T cell effector-memory re-expressing CD45RA+ (TEMRA) [23].

No significant differences in clinical characteristics existed at baseline between the peg-IFNα and the no-therapy group (Table 1). Also, no differences existed in TL between these two groups at screening (Fig. S1A). However, there was no correlation between HCV viremia levels and BMI (data not shown), suggesting that BMI and viremia are independent factors associating with T cell TL in chronic HCV infection.

Sustained IFNα therapy increased loss of telomere length

To determine whether IFN therapy affected telomere erosion, the rate of change in TL in CD4+ and CD8+ T lymphocyte subsets following sustained peg-IFNα therapy was assessed. Based on previous reports, we subdivided our subjects into three age categories: 50 years, 50 to 55 years, and >55 years of age at screening (Fig. 1). No differences in telomerase activity were observed among these age groups.

Age dependence of accelerated telomere length loss

To assess the effects of age, treatment group, and TL changes, mixed-effects statistical analyses were performed with results indicating a significant age-related IFN-effect on TLs (data not shown). However, linear model fitting assumptions inherent to a multivariate, mixed-effects model were not consistent with the non-linear TL loss data across the three time points. We then partitioned the data set into three age categories: <50 years, 50 to 55 years, and >55 years of age at screening (Fig. 5). The 50–55 year partition was centered on the average age of our subjects (Table 1), with the age partition boundaries selected to roughly balance the numbers of subjects in each partition. This age-partitioned analysis corroborated the mixed-effects model results that accelerated TL loss in the peg-IFNα group was seen in subjects <50 years old and was lost with increasing age in both CD4+ and CD8+ naive and memory compartments.

No difference in telomerase activity

We asked whether effects of long-term IFN therapy on telomerase activity (TA) could explain the accelerated TL loss. As resting peripheral blood T cells directly express little or no detectable TA, we analyzed TA after in vitro activation as an
Figure 1. Telomere length (TL) measurement using modified flowFISH. (A) FlowFISH cytometry gating strategy used to assess TL in CD4+ and CD8+ T cells. Singlet cells in a G0/G1 (diploid DNA content) gate were further selected using a lymphocyte gate based on forward and side scatter. Flow scatter plots of CD4+ by CD8+ staining with and without flowFISH hybridization are shown. TL estimates in molecules of equivalent soluble fluorescence (MESF) in CD4+ and CD8+ populations. (B) Linear regression analysis of naïve (CD45RA+ CD57−) CD4+ (circles) and naïve CD8+ (squares) TL at screening for cHCV subjects (n = 29, left panel) and healthy, age-matched donors (n = 19, right panel) versus age at blood draw. (C) FlowFISH-determined baseline TL estimates within total CD4+ and CD8+ T lymphocytes and indicated subpopulations for all 29 HALT-C subjects at screening. Graphs are box-whisker 10–90 percentile with outliers.

doi:10.1371/journal.pone.0020922.g001
indication of a possible durable effect of peg-IFNα therapy (see supporting file Methods S1 for details). No difference in TA as a result of in vitro activation was detected between the two treatment groups (Fig. S2).

**Table 1.** Patient characteristics at baseline and subsequent group assignment.

| Patient Group statistic | All | IFNα therapy | No therapy | p value* |
|-------------------------|-----|--------------|------------|----------|
| n                       | 29  | 14           | 15         |          |
| Age                     | 52.2 ± 6.3 | 52.1 ± 5.9 | 52.4 ± 7.0 | 0.88     |
| Gender (male:female)    | 24:5 |              |            |          |
| BMI (kg/m²)             | 30.2 ± 5.0 | 32.0 ± 4.5 | 28.5 ± 5.1 | 0.09     |
| Dur. Infection (years)  | 32.8 ± 8.3 | 30.0 ± 6.7 | 35.1 ± 5.0 | 0.17     |
| ALT (IU/L)              | 86.3 ± 42.8 | 95.9 ± 47.0 | 77.4 ± 37.9 | 0.30     |
| log10HCV (copies/mL)    | 6.6 ± 0.46 | 6.7 ± 0.5  | 6.4 ± 0.4  | 0.09     |
| Ishak fibrosis score    | 3.5 ± 0.95 | 3.6 ± 0.9  | 3.4 ± 1.1  | 0.48     |

Values are mean ± standard deviation except gender. ALT, blood alanine aminotransferase; BMI, body mass index. *P-value for all IFNα therapy to no-therapy group comparisons by Mann-Whitney test, except gender analyzed by Fisher’s exact test. †Duration of infection unavailable for three patients, two in IFNα-therapy and one in no therapy.

**Discussion**

In subjects with cHCV infection, sustained peg-IFNα therapy (90 μg/week) was associated with an increased rate of TL loss in both CD4+ and CD8+ T cell subsets. Additionally, based on a single intermediate time-point, this IFNα therapy-enhanced TL loss was fully concentrated in the initial 21 months. The delineation of TL changes in T cell CD45RA+/CD57− subsets shows that declines in the T cell TL are not shifts in naïve (long TL); versus memory (shortened TL) T cell proportions, but true decreases in TL with the greatest impact on the naïve T cell subsets. The lack of an accelerated TL loss effect in naïve T cells in the second interval in the peg-IFNα group suggests that a new homeostasis is reached. Our findings are consistent with the telomere erosion effects of increased lymphocyte turn-over in response to a sustained lymphopenic signal as predicted from the mathematical models of de Boer and Noest [29]. Increased T cell turn-over would also account for our observation that sustained peg-IFNα treatment inhibited the expansion of CD8+ CD45RA+ CD57+ TEMRA cells, a phenomenon observed in the control group.

By HALT-C trial design, subjects in both groups received combination therapy with peg-IFNα (180 μg/week) plus ribavirin for the initial 24 weeks of the study; PBMC were not available from other intermediate time points. Therefore, it is possible that accelerated TL loss occurred in both groups during the initial phase of lead-in therapy. Average TL could then have rebounded in the control group between the end of therapy at week 24 and month 21 whereas ongoing, lower-dose peg-IFNα therapy maintained the lower average TL (or suppressed a TL recovery) in the therapy group. Consistent with this interpretation, the decline in TL was slower during the second interval than in the earlier interval in the therapy group. If this interpretation is correct, it is impossible to determine whether the effect of the initial therapy on TL is attributable to the higher dose of peg-IFNα or to ribavirin. Nevertheless, sustained peg-IFNα was clearly associated with accelerated TL loss during the subsequent 3½ years in comparison with the control group.

An important finding from our study is the correlation of baseline T cell TL in these cHCV subjects with viremia and BMI. It should be noted that subjects in the randomization phase of the trial had endured HCV viremia for decades (range: 14–51 years) and failed to achieve SVR during combination peg-IFNα-ribavirin therapy. The absence of a negative correlation of baseline T cell TL with age in this cohort may therefore reflect stronger impacts of long-term viremia and the generally high levels of obesity in these subjects.

We speculate that the negative association between serum viral RNA levels and baseline TL reflects chronic elevated T cell activation, cell death, and proliferation due to persistent presentation of HCV antigens in a dose-dependent manner. Alternatively, higher circulating viral RNA levels may also drive greater endogenous type I IFN production. A negative correlation of BMI with baseline TL in naïve T cells could also reflect chronic inflammation in obesity [30]. Chronic inflammation as a result of obesity may lead to decreased thymic output [31], inducing increased homeostatic proliferation of naïve T lymphocytes and thus a decrease in TL through replicative erosion.

Another possible explanation for the lack of an age-dependent TL association in this cohort relates to evidence that short telomeres play a causal role in a variety of age-related diseases [32,33,34,35]. Thus it is plausible that study inclusion criteria biased the enrolled study population away from subjects with very short telomeres.
Elevated ALT levels in cHCV are indicative of hepatocellular inflammation and necrosis [12]. Our finding of a correlation of serum ALT levels with naïve T cell TL loss in the control group likely reflects T cell responses to infected HCV-infected hepatocytes and the extended time frame over which telomere lengths were analyzed. This relationship was possibly obscured in the peg-IFNα group by the effects of continuous therapy. The correlation between TL changes and ALT, which could be due to T cell clonal exhaustion, immunosenescence, or a combination of these and/or other immunological factors, suggests that normalization of liver enzymes levels in the blood may coincide with a reduction in T cell turn-over and thus reduced telomere erosion.

We hypothesized that maintenance peg-IFNα therapy would cause increased TL loss in T cells as a result of inhibition of telomerase activity [4,36]. However, we did not find a significant difference between the peg-IFNα and control groups in telomerase activity in PBMC stimulated in vitro. It is quite possible that using in vitro-stimulated PBMC the telomerase assay fails to detect an inhibitory effect of peg-IFNα therapy that existed in vivo. In any case, a telomerase inhibition mechanism falls short in explaining the predominance of an accelerated TL loss on naïve T cells in these older adults where thymic output of new, longer telomere naïve T cells is thought to be negligible.

We further found a decline in the peg-IFNα effect on TL loss with increasing age. Increasing age is associated with increased failure rates of IFN therapy for cHCV [14]. This may suggest that elevated TL erosion caused by peg-IFNα is counteracted by replicative senescence deferentially within T cell compartments.

Figure 2. Screening T cell telomere lengths inversely correlated with hepatitis C viral RNA levels and BMI. (A) TL in total CD4+ (gray circles) and total CD8+ (black squares) T cells from the screening (S00) time point versus screening HCV RNA levels, (B) TL in naïve CD4+ (circles) and CD8+ (squares) CD45RA+CD57- subsets versus screening HCV RNA levels, and (C) TL in memory CD4+ (circles) and CD8+ (squares) CD45RA-CD57- subset versus screening HCV RNA levels. (D) Baseline body-mass index (BMI, in kilograms per meter squared) from screening assessment inversely correlated with naïve phenotype CD4+ (gray circles) and CD8+ (filled squares) T cells. Correlation (r-squared) and p values are from linear regression testing with best-fit lines as shown.
doi:10.1371/journal.pone.0020922.g002
The delineation of TL loss effect by CD4\(^+\) and CD8\(^+\) T cell subset by age group results suggest a hierarchy of age-dependent T cell senescence in chronic HCV patients. Thus senescence may occur in the order: memory CD4\(^+\), memory CD8\(^+\), naive CD4\(^+\), naive CD8\(^+\) in this HCV setting. Further, this result of the memory CD4\(^+\) T cell compartment becoming refractory to IFN-induced TL decreases as a marker of immunosenescence onset is consistent with the finding by Hoare, et al. where they found TL in CD4\(^+\)CD45RO\(^+\) memory T cells was a stronger predictor of SVR with IFN therapy than TL in any other T cell subset [37].

Enhanced T cell TL loss in subjects who received long-term peg-IFN\(\alpha\) therapy suggests that T cells in these subjects have reduced proliferative reserve. Subjects receiving type I IFN therapy are known to be more susceptible to bacterial infections; this has been attributed to neutropenia, but several studies have shown no temporal correlation between neutrophil count and infections [38,39]. Diminished memory T cells and proliferative reserve related to naive T cell TL loss, as shown in this study, could contribute to the increased susceptibility to infection and disease while on interferon therapy. Importantly, diminished naive T cell proliferative TL reserve incurred under sustained IFN therapy may persist well beyond the end of therapy. Indeed, as age-related thymic involution severely limits production of new, long telomere, naive T cells [37], a sustained accelerated TL erosion thus may leave a permanently degraded naive T cell compartment. Support for this possibility comes from a recent analysis of a subset of patients from the HALT-C cohort prospectively followed for more than 5 years after the trial. That study showed rates of non-liver-related death were significantly higher (\(p = 0.01\)) among patients with liver fibrosis who received the 3.5 year peg-IFN\(\alpha\) therapy compared to similar patients in the control arm [40].

Although extended type I interferon therapy beyond 48 weeks in the HCV settings is not typically warranted, there are additional clinical settings where extended interferon therapy is utilized. Some examples include relapsing-remitting multiple sclerosis and melanoma [41,42]. Accordingly, as extended type I interferon is clinically practiced, our findings suggest that additional studies of the effects of peg-IFN\(\alpha\) therapy on age-related T cell senescence are warranted.

### Materials and Methods

#### Ethics Statement

All subjects provided written, informed consent for participation under protocols approved by the institutional review boards of all participating study centers and conformed to the ethical guidelines of the 1975 Declaration of Helsinki. Specifically, the human-derived PBMC samples used in this telomere length HALT-C ancillary study came from the following institutions with formal Institutional Review Board approval obtained from all: Human Subjects/IRB, University of Massachusetts Medical School, Worcester, MA; Human Subjects Protection Office, University of Connecticut Health Center, Farmington, CT; Biomedical IRB, Saint Louis University, Saint Louis, MO; Institutional Review Board, The University of Texas Southwestern Medical Center, Dallas, TX; Institutional Review Board, University of Southern California Health Sciences Campus, Los Angeles, CA; Institutional Review Board for Human Subject Research, University of Michigan Medical School, Ann Arbor, MI.
Subjects and study design

The HALT-C trial design has been described in detail elsewhere [10]. Initial enrollment criteria required all subjects to have histologically-confirmed liver fibrosis or cirrhosis (Ishak score ≥3). Subjects who remained viremic after 6 months of peg-IFNα plus ribavirin therapy were randomized either to continued maintenance-dose (90 mg/week) peg-IFNα for an additional 3.5 years or a monitor-only control group, for a total study duration of 48 months per patient. Neither subjects nor clinicians were blinded to treatment assignment. Peripheral blood mononuclear cell (PBMC) samples for telomere length analysis came from a representative subset of the HALT-C cohort consisting of 29 patients who successfully completed the 48 month randomization phase from three time points within the study period: screening (S00), month 21 (M21), and month 45 (M45).

PBMC samples

Subjects from each randomization group, peg-IFNα treatment and control, were selected as matched-pairs, based on age, gender, and Ishak fibrosis score (Table 1). Subjects for the peg-IFNα therapy group were selected for high compliance (>80%). For TL analysis, we were blinded to treatment group assignment, patient characteristics, and chronological order for each patient’s PBMC until after the completed TL data set was returned to the HALT-C Data Coordinating Center. Patient data (Table 1) included: age at enrollment and PBMC collections, gender, race, body mass index (BMI) at enrollment, estimated duration of HCV infection, serum alanine amino transferase (ALT) levels, serum HCV RNA levels, and Ishak fibrosis score [15,43,44]. Additionally, PBMC from a separate, healthy cohort of 19 subjects matching the age range of the HALT-C subjects were collected with written, informed consent under University of Massachusetts Medical School Institutional Review Board-approved protocols.

Telomere length measurements

TL was measured using a modified flowFISH assay [21]. 4 × 10⁶ PBMC from each sample were stained with Alexa700-anti-hCD4 and APC-Alexa750-anti-hCD8 (eBiosciences, San Diego, CA), treated with 1 mM suberic acid bis(3-sulfo-N-hydroxysuccinimide ester) sodium salt crosslinker then quenched with 50 mM Tris-HCl. Cells were fixed in 4% formaldehyde and 0.05% saponin for 25 minutes at 4°C. All samples were incubated in lithium-based RNase buffer plus 0.05% saponin with 2 μL RNase1 (Promega, Madison, WI) for two hours. Samples were then divided to three probe (+) tubes and one probe (−) tube for hybridization in 70% formamide, 150 mM lithium-chloride buffer at 82°C for 12 minutes. Probe (+) tubes contained Cy5-OO-(CCCTAA) 3-EE peptide nucleic acid probe at 0.5 mg/mL. After overnight cooling, samples were washed twice in 70% formamide buffer then with 2 mL PBS, stained with PE-Cy7-anti-hCD45RA antibody and PE-anti-hCD57, and resuspended in PBS-BSA containing 0.1 μg/mL 4’,6-diamidino-2-phenylindole (DAPI).

Sample analysis

Samples were analyzed with a FACS-Aria (BD, San Jose, CA) cytometer with performance verified prior to each assay using...
calibration beads. A minimum of 20,000 lymphocyte-gated events were collected for every tube. Each sample probe (-) tube mean fluorescence intensity (MFI) was subtracted from the average MFI of the matching three probe (+) tubes to obtain a specific MFI. A minimum of 30 events per gated population was employed to include a resulting MFI in an analysis; this limit only affected CD57+ subsets. Specific MFI values were converted to molecules of equivalent soluble fluorescence (MESF) using linear calibration beads-derived MFI to MESF linear equation. A healthy donor PBMC sample analyzed in triplicate in four of the eight total flow FISH analyses provided inter-assay and intra-assay coefficients of variation (CV). Inter-assay CV for all CD4+ and all CD8+ T cells were 7.4% and 6.6% respectively. Intra-assay CV for all CD4+ and all CD8+ T cells were 1.1% and 1.3% respectively. PBMC samples from each subject’s three time points were run in the same assay to minimize inter-assay variation.

Telomerase activity measurement in in vitro activated T lymphocytes

See supporting file Methods S1.

Figure 5. TL loss with therapy was lost with increasing age in a T cell subset-dependent manner. Naïve CD4+ (upper left plot), memory CD4+ (lower left plot), naive CD8+ (upper right plot), and memory CD8+ (lower right plot) T cell change in telomere length (delta TL) from screening to month 45 from subjects in both treatment groups. Each symbol is an individual subject’s delta TL for that T cell subset. Filled symbols are IFNα treatment group subjects, open symbols are control group subjects. Horizontal bars are mean values.

doi:10.1371/journal.pone.0020922.g005

Figure 6. Serum ALT correlates with changes in naïve T cell telomere lengths in the control group. Average serum alanine aminotransferase (ALT) levels during the randomization phase correlated with telomere length loss (delta TL) in the no-therapy control group (right-hand panel), but not in the IFN therapy group (left-hand panel). Delta TL shown is from screening (S00) to month 45 (M45).

doi:10.1371/journal.pone.0020922.g006
Data and statistical analysis

Although subjects within the two randomization groups were initially selected as matched pairs, TL data from one subject was unusable and therefore unpaired analyses were conducted. For linear regression analyses, fitted lines, correlation values, and p values were from linear regression testing. Statistical analyses were performed using Prism v5.0 (Graphpad, La Jolla, CA) with p values <0.05 considered statistically significant. All statistical tests were two-tailed.

Supporting Information

Figure S1 Baseline telomere lengths and CD57+ frequencies were not different at screening between the two groups. (A) Subject telomere lengths at screening. Each symbol is an individual subject’s TL measured by flowFISH in that T cell subset. P values are from unpaired t test analysis. Horizontal bars are mean values. (B) CD57+ subset distribution within respective CD4+ and CD8+ T cell populations from screening (S00), month 21 (M21), and month 45 (M45). Plots are box and whiskers 5–95 percentile bar graphs showing outlier values; peg-IFNα therapy subjects shown as empty bars; control group subjects, filled bars. RA+ or RA− indicates CD45RA+ or CD45RA− respectively, 57+ indicates CD57+. (JPG)

Figure S2 Induced telomerase activity in PBMC between treatment groups was not different at any time point. Telomerase activity (TA) was assessed in in vitro stimulated PBMC from each of the three time points, screening (S00), month 21 (M21), and month 45 (M45), and the results analyzed between treatment groups as shown. Statistical p values are from Mann-Whitney non-parametric analysis. PBMC were stimulated with plate-bound anti-CD3 plus anti-CD28 for 3 days and then tested for TA by a commercial real-time PCR-based TRAP assay as described in Methods S1. (JPG)

Methods S1 Telomerase activity measurement in in vitro activated T lymphocytes. (DOC)

Acknowledgments

We would like to thank Marcia Woda for expert assistance with flow cytometry and instrument configuration.

Author Contributions

Conceived and designed the experiments: ALR AM. Performed the experiments: JMO. Analyzed the data: JO JAP. Contributed reagents/materials/analysis tools: HLB. Wrote the paper: JMO AM ALR.

This is publication number 61 from the HALT-C Trial Study Group. The HALT-C trial was registered with clinicaltrials.gov (#NCT00006161).

The following individuals were instrumental in the planning, conduct and/or care of patients enrolled in the HALT-C study at each of the participating institutions as follows:

University of Massachusetts Medical Center, Worcester, MA: (Contract N01-DK-9-2326) Gyongyi Szabo, MD, Barbara F. Banner, MD, Maureen Cornier, RN, Donna Giansiracusa, RN

University of Connecticut Health Center, Farmington, CT: (Grant M01RR-06192) Gloria Borders, RN, Michelle Kelley, RN, ANP

Saint Louis University School of Medicine, St Louis, MO: (Contract N01-DK-9-2324) Adrian M. Di Bisceglie, MD, Bruce Bacon, MD, Brent Neuschwander-Tetri, MD, Elizabeth M. Brunt, MD, Debra King, RN

University of Texas Southwestern Medical Center, Dallas, TX: (Contract N01-DK-9-2321, Grant M01RR-00653, Grant 1 UL1 RR024902-01, North and Central Texas Clinical and Translational Science Initiative) William M. Lee, MD, Thomas E. Rogers, MD, Peter F. Malet, MD, Janel Shelton, Nicole Crowder, LVN, Riksa Elbein, RN, BSN, Nancy Liston, MPH

University of Southern California, Los Angeles, CA: (Contract N01-DK-9-2325) Grant M01RR-00404, Karen L. Lindsay, MD, MMM, Sugantha Govindarajan, MD, Carol B. Jones, RN, Susan L. Mlstein, RN

University of Michigan Medical Center, Ann Arbor, MI: (Contract N01-DK-9-2323, Grant M01RR-00042, Grant 1 UL1 RR024906, Michigan Center for Clinical and Health Research) Anna S. Lok, MD, Robert J. Fontana, MD, Joel K. Greenmon, MD, Pamela A. Richtmyer, LPN, CCRC, R. Tess Bonham, BS

National Institute of Diabetes and Digestive and Kidney Diseases, Division of Digestive Diseases and Nutrition, Bethesda, MD: James E. Everhart, MD, Leonard B. Seeff, MD, Patricia R. Robuck, PhD, Jay H. Hoofnagle, MD, Elizabeth C. Wright, PhD

University of Washington, Seattle, WA: (Contract N01-DK-9-2318) Chihiro Morishima, MD, David R. Gretch, MD, PhD, Minjun Chung Apodaca, BS, ASCP, Rohit Shankar, BC, ASCP, Natalia Antonov, M. Ed.

New England Research Institutes, Watertown, MA: (Contract N01-DK-9-2328) Kristin K. Snow, MSc, ScD, Anne M. Stoddard, ScD, Linda Massey, Teresa M. Curto, MSW, MPH, Margaret C. Bell, MS, MPH, Deepa Naishadham, MA, MS

Armed Forces Institute of Pathology, Washington, DC: Zachary D. Goodman, MD, PhD, Fanny Monge, Michelle Parks

Data and Safety Monitoring Board Members: (Chair) Gary L. Davis, MD, Guadalupe Garcia-Tsao, MD, Michael Kutner, PhD, Stanley M. Lemon, MD, Robert P. Perrillo, MD

Telomere Loss following IFN Therapy
References

1. de Lange T (2005) Shelterin: the protein complex that shapes and safeguards human telomeres. Genes Dev 19: 2100-2110.
2. Hodes RJ, Hatooek KS, Weng NP (2002) Telomeres in T and B cells. Nat Rev Immunol 2: 699-706.
3. Weng NP (2008) Telomere and adaptive immunity. Mech Ageing Dev 129: 69-66.
4. Xu D, Erickson S, Szepe M, Gruber A, Sandle J et al. (2000) Interferon alpha down-regulates telomerase reverse transcriptase and telomerase activity in human malignant and nonmalignant hematopoietic cells. Blood 96: 4313–4318.
5. Hirsch RL, Johnson KP (1986) The effects of long-term administration of recombinant alpha-2 interferon on lymphocyte subsets, proliferation, and suppressor cell function in multiple sclerosis. J Interferon Res 6: 171-177.
6. Boyman O, Lotourneau S, Kriem S, Sprent J (2009) Homeostatic proliferation and survival of naive and memory T cells. Eur J Immunol 39: 2088-2094.
7. Hooghegle JS, Steelf LS (2006) Peginterferon and ribavirin for chronic hepatitis C. N Engl J Med 355: 2444-2451.
8. Lok AS, Seef LB, Morgan TR, di Bisceglie AM, Sterling RK et al. (2009) Incidence of hepatocellular carcinoma and associated risk factors in hepatitis C-related advanced liver disease. Gastroenterology 136: 138-148.
9. di Bisceglie AM, Shiffman ML, Everson GT, Lindsay KL, Everhart JE et al. (2008) Prolonged therapy of advanced chronic hepatitis C with low-dose peginterferon. N Engl J Med 359: 2829-2841.
10. Lee WM, Dienstag JL, Lindsay KL, Lok AS, Bonvorsky HL et al. (2004) Evolution of the HALT-C Trial: pegylated interferon as maintenance therapy for chronic hepatitis C in previous interferon nonresponders. Control Clin Trials 25: 472-492.
11. Everhart JE, Lok AS, Kim HY, Morgan TR, Lindsay KL et al. (2009) Weight-related effects on disease progression in the hepatitis C antiviral long-term treatment against cirrhosis trial. Gastroenterology 137: 549-557.
12. Jamal MM, Soni A, Quinn PP, Wheeler DE, Arora S et al. (1999) Clinical features of hepatitis C-infected patients with persistently normal alanine transaminase levels in the Southeastern United States. Hepatology 30: 1307-1311.
13. Lin R, Liddle C, Byth K, Farrell GC (1996) Virus and host factors are both important determinants of response to interferon treatment among patients with chronic hepatitis C. J Viral Hepat 3: 85-96.
14. Romro R, Rumi M, Colombo M (1995) Alpha interferon treatment of chronic hepatitis C. Biomed Pharmacother 49: 111-115.
15. Rothman AL, Morishima C, Bonvorsky HL, Polak S J, Ray R et al. (2005) Associations among clinical, immunological, and viral quasispecies measurements in advanced chronic hepatitis C. Hepatology 41: 617-625.
16. Vandelli C, Renz F, Braun HB, Tumimetzky S, Albrecht M et al. (1999) Prediction of successful outcome in a randomized controlled trial of the long-term efficacy of interferon alpha treatment for chronic hepatitis C. J Med Viral 58: 26-34.
17. Tillmann HL, Mannn MP, Rudolph KL (2005) Merging models of hepatitis C virus pathogenesis. Semin Liver Dis 25: 84-92.
18. Valdes AM, Andrew T, Gardner JP, Kimura M, Oelsner E et al. (2005) Telomere shortening and obesity in memory T cells subsets in young and old people. Immun Ageing 3: 6.
19. Weng NP, Levine BL, June CH, Hodes RJ (1995) Human naive and memory T lymphocytes differ in telomeric length and replicative potential. Proc Natl Acad Sci U S A 92: 11091–11094.
20. Aubert G, Landsorp PM (2000) Telomeres and aging. Physiol Rev 88: 557-579.
21. Brinchley JM, Karandikar NJ, Betts MR, Ambrozak DR, Hill BJ et al. (2003) Expression of CD57 defines replicative senescence and antigen-induced apoptotic death of CD8+ T cells. Blood 101: 2711-2720.
22. Le Pital Y, Pathier D, Lecureuil C, Combadiere C, Debe M et al. (2006) High cytoytic and specific migratory potencies of senescent CD8+ CD57+ cells in HIV-infected and uninfected individuals. J Immunol 177: 5145-5154.
23. Menaplus B, Weiadenbach H, Beckh H, Kern P, Moller P et al. (2004) Oligodendrocy CD10+ T-cell expansion in patients with chronic hepatitis C is associated with liver pathology and poor response to interferon-alpha therapy. J Clin Immunol 24: 258-271.
24. De Boer RJ, Noest AJ (1986) T cell renewal rates, telomerase, and telomere length shortening. J Immunol 160: 5832-5837.
25. Holmslagle JS, Erday E (2006) Nutrient sensing and inflammation in metabolic diseases. Nat Rev Immunol 8: 923-934.
26. Dixit AV (2008) Adipose-immune interactions during obesity and caloric restriction: reciprocal mechanisms regulating immunity and health span. J Leukoc Biol 84: 892-902.
27. Gilley D, Herbert BS, Hida N, Tanaka H, Reid T (2008) Factors impacting human telomere homeostasis and age-related disease. Mech Ageing Dev 129: 27-34.
28. Farzanleh-R Ans J, In J, Erel A, Laksam K, Blackburn E et al. (2009) Telomere length trajectory and its determinants in persons with coronary artery disease: longitudinal findings from the heart and soul study. PLoS One 5: e8612.
29. Huetz J, de Boer RA, van Velshuizen DJ, van Gihl WH, van der Harst P (2010) The emerging role of telomere biology in cardiovascular disease. Front Biosci 15: 35-43.
30. Zee RY, Michaud SE, Germer S, Rikker PM (2009) Association of shorter mean telomere length with risk of incident myocardial infarction: a prospective, nested case-control approach. Clin Chim Acta 403: 139-141.
31. Reed JR, Yukanovnic-Sticic M, Fletcher JM, Soares MV, Cook JF et al. (2004) Telomere erosion in memory T cells induced by telomerase inhibition at the site of antigenic challenge in vivo. J Exp Med 199: 1433-1443.
32. Hoare M, Gelson WT, Das A, Fletcher JM, Davies SE et al. (2010) CD4+ T-lymphpocyte telomere length is related to fibrosis stage, clinical outcome and treatment response in chronic hepatitis C virus infection. J Hepatol 53: 292-300.
33. Soza A, Everhart JE, Ghany MG, Doo E, Heller T et al. (2002) Neutropenia and mortality in patients with advanced chronic hepatitis C treated with pegylated interferon. J Leukoc Biol 84: 4313-4318.
34. Zee RY, Michaud SE, Germer S, Rikker PM (2009) Association of shorter mean telomere length with risk of incident myocardial infarction: a prospective, nested case-control approach. Clin Chim Acta 403: 139-141.
35. Reed JR, Yukanovnic-Sticic M, Fletcher JM, Soares MV, Cook JF et al. (2004) Telomere erosion in memory T cells induced by telomerase inhibition at the site of antigenic challenge in vivo. J Exp Med 199: 1433-1443.
36. Hoare M, Gelson WT, Das A, Fletcher JM, Davies SE et al. (2010) CD4+ T-lymphpocyte telomere length is related to fibrosis stage, clinical outcome and treatment response in chronic hepatitis C virus infection. J Hepatol 53: 292-300.
37. Soza A, Everhart JE, Ghany MG, Doo E, Heller T et al. (2002) Neutropenia during combination therapy of interferon alfa and ribavirin for chronic hepatitis C. Hepatology 36: 1277-1279.
38. Antonini MG, Babudieri S, Maida I, Baiguera C, Zanini B et al. (2008) Telomere loss following interferon therapy. J Leukoc Biol 84: 892-902.
39. Delgado-Borrego A, Jordan SH, Negre B, Healey D, Lin W et al. (2010) Telomere Loss following IFN Therapy